Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: Results from a German case-control study

Journal of Family Planning and Reproductive Health Care

Volumn 36, Issue 3, 2010, Pages 123-129

  Dinger, Jürgen ^a   Assmann, Anita ^a   Möhner, Sabine ^a   Minh, Thai Do ^a  

^a ZEG Berlin Center for Epidemiology and Health Research   (Germany)

Author keywords

Case control study; Dienogest; Drospirenone; Oral contraceptives; Venous thromboembolism

Indexed keywords

DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ANDROSTANE DERIVATIVE; DIENOGEST; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; LEVONORGESTREL; MINERALOCORTICOID ANTAGONIST; NANDROLONE; ORAL CONTRACEPTIVE AGENT;

ACCIDENT; ADULT; ANAMNESIS; ANGIOGRAPHY; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMMUNITY CARE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ECHOGRAPHY; FAMILY HISTORY; FEMALE; GERMANY; HEREDITY; HUMAN; IMMOBILIZATION; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL RECORD; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PATIENT REFERRAL; PHLEBOGRAPHY; PREGNANCY; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT DURATION; VARICOSIS; VENOUS THROMBOEMBOLISM; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROSTENES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GERMANY; HUMANS; LEVONORGESTREL; LOGISTIC MODELS; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NANDROLONE; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 77954835244     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118910791749416     Document Type: Article

References (38)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
2. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-88. (Pubitemid 3016199)
3. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593. (Pubitemid 26001840)
4. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
5. Edwards RG, Cohen J. Reproductive choices in 2000: the relative safety of current oral contraceptives. Hum Reprod Update 1999; 5: 563-564.
6. Heinemann LA. The changing scene - an unnecessary pill crisis. Hum Reprod Update 1999; 5: 746-755.
7. Heinemann LA, Lewis MA, Assmann A, Thiel C. Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002; 65: 207-214. (Pubitemid 34258541)
8. Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179: 1086-1097.
9. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-1499. (Pubitemid 29265441)
10. Heinemann LAJ, Dinger JC, Assmann A, Do Minh T. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". Contraception 2010; 81: 401-407.
11. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88. (Pubitemid 27023424)
12. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
13. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. Effects of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives: results of the MEGA case-control study. BMJ 2009; 339: b2921.
14. Dinger J. Oral contraceptives and venous thromboembolism: old questions revisited. J Fam Plann Reprod Health Care 2009; 35: 211-213.
15. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36: 33-38.
16. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344-354. (Pubitemid 46551071)
17. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-593. (Pubitemid 47359582)
18. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5-13. (Pubitemid 26230794)
19. Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 1997; 12: 2347-2357.
20. Van Lunsen HW. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestagens. Eur J Contracept Reprod Health Care 1996; 1: 39-45.
21. Heinemann LA, Lewis MA, Assman A, Gravens L, Guggenmoos-Holzmann I. Could preferential prescribing and referral behaviour explain the elevated thrombosis risk found to be associated with third generation oral contraceptives? Pharmacoepidemiol Drug Saf 1996; 5: 285-294.
22. Jamin C, de Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996; 54: 55-56. (Pubitemid 26235253)
23. Jamin C, Benifla JL, Madelenat P. The role of selective prescribing in the increased risk of VTE associated with third-generation oral contraceptives. Hum Reprod Update 1999; 5: 664-671. (Pubitemid 30034889)
24. Heinemann LAJ, Garbe E, Farmer R, Lewis M. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 2000; 5: 183-191.
25. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38.
26. Golbs S, Domhardt R, Presl J, Ganev M, Wisser KH, Zimmermann T. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic. Methods Find Exp Clin Pharmacol 2002; 24: 689-696. (Pubitemid 36188278)
27. Golbs S, Domhardt R, Radowicky S, Kaluzny Z, Wisser KH, Zimmermann T. Clinical findings with the oral contraceptive combination ethinylestradiol/ dienogest in Poland. Methods Find Exp Clin Pharmacol 2002; 24: 585-592. (Pubitemid 36109398)
28. Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999; 4: 155-164.
29. International Society for Pharmacoepidemiology. Guidelines for Good Epidemiology Practices (GPP). 1996. http://www.pharmacoepi.org/resources/ guidelines-08027.cfm [Accessed 17 March 2010].
30. International Epidemiological Association (IEA). Good Epidemiological Practice (GEP). IEA Guidelines for Proper Conduct of Epidemiological Research. 2007. http://www.ieatemp.com/pdfs/GEPNov07.pdf [Accessed 17 March 2010]
31. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet 2005; 365: 1429-1433. (Pubitemid 40523738)
32. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57-68.
33. Strom BL. Appendix A - Sample size tables. In: Strom BL (ed.), Pharmacoepidemiology. Chichester, UK: John Wiley & Sons, 1994; 659-692.
34. Heinemann LA, Moehner S, Assmann A, Heinemann K. Use of oral contraceptives containing dienogest and risk of venous thromboembolism - an extended summary report of a case-control study. Life and Medical Science Online 2001, 2: DOI 10.1072/LO211329.
35. Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991 133: 635-648.
36. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives - an approach to specifying rates. Eur J Epidemiol 2005; 20: 509-516. (Pubitemid 40933928)
37. Schwarz T, Siegert G, Oettler W, Halbritter K, Beyer J, Frommhold R, et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003; 163: 2759-2764.
38. Heinemann LA, Garbe E, Farmer R, Lewis MA. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 2000; 5: 183-191.